Highly active anti retroviral therapy including nevirapine once daily versus twice daily after at least 12 weeks of nevirapine twice daily. A randomized, open, multicentre trial

Trial Profile

Highly active anti retroviral therapy including nevirapine once daily versus twice daily after at least 12 weeks of nevirapine twice daily. A randomized, open, multicentre trial

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2009

At a glance

  • Drugs Nevirapine (Primary)
  • Indications HIV infections; HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms NODy
  • Most Recent Events

    • 01 Apr 2009 Results published in the Journal of Acquired Immune Deficiency Syndromes.
    • 03 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top